Giri S, Sen S, Chi C, Kim H, Yun S, Park S, et al. Chlorophytum borivilianum Polysaccharide Fraction Provokes the Immune Function and Disease Resistance of Labeo rohita against Aeromonas hydrophila. J Immunol Res. 2015;2015:256510 pubmed publisher

Fang S, Niu Y, Zhang W, Zhang Y, Yu L, Zhang Y, et al. Liposome-like nanocapsules of dual drug-tailed betaine for cancer therapy. Int J Pharm. 2015;493:460-5 pubmed publisher

Tadros M, Al Mahallawi A. Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: Development, preliminary safety evaluations and preclinical pharmacokinetic studies. Int J Pharm. 2015;493:439-50 pubmed publisher

Paiva C, Godbersen J, Berger A, Brown J, Danilov A. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis. 2015;6:e1807 pubmed publisher

Sachweh M, Stafford W, Drummond C, McCarthy A, Higgins M, Campbell J, et al. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget. 2015;6:16488-506 pubmed

Yeung M, Hurren R, Nemr C, Wang X, Hershenfeld S, Gronda M, et al. Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis. 2015;20:811-20 pubmed publisher

Herold M, Scholz C, Rothmann F, Hirt C, Lakner V, Naumann R. Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. J Cancer Res Clin Oncol. 2015;141:1689-95 pubmed publisher

Banbury L, Shou Q, Renshaw D, Lambley E, Griesser H, Mon H, et al. Compounds from Geijera parviflora with prostaglandin E2 inhibitory activity may explain its traditional use for pain relief. J Ethnopharmacol. 2015;163:251-5 pubmed publisher

Weiler S, Ademokun J, Norton J. ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro. Mol Cancer. 2015;14:30 pubmed publisher

Rehman S, Sarwar T, Ishqi H, Husain M, Hasan Z, Tabish M. Deciphering the interactions between chlorambucil and calf thymus DNA: a multi-spectroscopic and molecular docking study. Arch Biochem Biophys. 2015;566:7-14 pubmed publisher

De Vrieze M, Verzele D, Szucs R, Sandra P, Lynen F. Evaluation of sphingomyelin, cholester, and phosphatidylcholine-based immobilized artificial membrane liquid chromatography to predict drug penetration across the blood-brain barrier. Anal Bioanal Chem. 2014;406:6179-88 pubmed publisher

Wang X, Zhang Q, Lin Q, Zhang Y, Zhang Z. Validated LC-MS/MS method for the simultaneous determination of chlorambucil and its prodrug in mouse plasma and brain, and application to pharmacokinetics. J Pharm Biomed Anal. 2014;99:74-8 pubmed publisher

van den Broek E, Oerlemans S, Nijziel M, Posthuma E, Coebergh J, van de Poll Franse L. Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands. Ann Hematol. 2015;94:45-56 pubmed publisher

Goede V, Fischer K, Hallek M. Chemoimmunotherapy for chronic lymphocytic leukemia. Author reply. N Engl J Med. 2014;370:2348-9 pubmed publisher

Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165:534-44 pubmed publisher

Satram Hoang S, Reyes C, Hoang K, Momin F, Skettino S. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol. 2014;93:1335-44 pubmed publisher

Zuravka I, Roesmann R, Sosic A, Wende W, Pingoud A, Gatto B, et al. Synthesis and DNA cleavage activity of Bis-3-chloropiperidines as alkylating agents. ChemMedChem. 2014;9:2178-85 pubmed publisher

Dertinger S, Phonethepswath S, Avlasevich S, Torous D, Mereness J, Cottom J, et al. Pig-a gene mutation and micronucleated reticulocyte induction in rats exposed to tumorigenic doses of the leukemogenic agents chlorambucil, thiotepa, melphalan, and 1,3-propane sultone. Environ Mol Mutagen. 2014;55:299-308 pubmed publisher

Masoodi M, Lee E, Eiden M, Bahlo A, Shi Y, Ceddia R, et al. A role for oleoylethanolamide in chronic lymphocytic leukemia. Leukemia. 2014;28:1381-7 pubmed publisher

Filip A, Ciseł B, Wasik Szczepanek E. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes. Clin Exp Med. 2015;15:73-83 pubmed publisher

Herting F, Friess T, Bader S, Muth G, Hölzlwimmer G, Rieder N, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014;55:2151-5160 pubmed publisher

Millard M, Gallagher J, Olenyuk B, Neamati N. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J Med Chem. 2013;56:9170-9 pubmed publisher

Mathieson P. Immunosuppression for membranous nephropathy - Authors' reply. Lancet. 2013;381:2163 pubmed publisher

Chen Z, Du X. Immunosuppression for membranous nephropathy. Lancet. 2013;381:2162-3 pubmed publisher

Cirillo M. Immunosuppression for membranous nephropathy. Lancet. 2013;381:2161 pubmed publisher

Remuzzi G, Ruggenenti P. ACP Journal Club. Prednisolone plus chlorambucil preserved renal function in membranous nephropathy. Ann Intern Med. 2013;158:JC9 pubmed publisher

Karpusas M, Axarli I, Chiniadis L, Papakyriakou A, Bethanis K, Scopelitou K, et al. The interaction of the chemotherapeutic drug chlorambucil with human glutathione transferase A1-1: kinetic and structural analysis. PLoS ONE. 2013;8:e56337 pubmed publisher

Metzgeroth G, Schneider S, Hofmann W, Hastka J. Globular intracytoplasmic inclusions in a patient with chronic lymphocytic leukaemia. Br J Haematol. 2013;161:302 pubmed publisher

Filatova E, Iakovlev S, Bonartsev A, Makhina T, Myshkina V, Bonartseva G. [Prolonged release of chlorambucil and etoposide from poly-3-oxybutyrate-based microspheres]. Prikl Biokhim Mikrobiol. 2012;48:662-7 pubmed

. A difficult trade off for adults with membranous nephropathy. BMJ. 2013;346:f248 pubmed publisher

Ruggenenti P, Remuzzi G. Idiopathic membranous nephropathy: back to the future?. Lancet. 2013;381:706-8 pubmed publisher

Howman A, Chapman T, Langdon M, Ferguson C, Adu D, Feehally J, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013;381:744-51 pubmed publisher

Zucca E, Conconi A, Laszlo D, Lopez Guillermo A, Bouabdallah R, Coiffier B, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013;31:565-72 pubmed publisher

Cortes B, Khelifa E, Clivaz L, Cazzaniga S, Saurat J, Naldi L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology. 2012;225:320-5 pubmed publisher

Hapgood G, Mooney E, Dinh H, Gin D, McLean C, Ting S. Leukaemia cutis in chronic lymphocytic leukaemia following varicella zoster virus reactivation. Intern Med J. 2012;42:1355-8 pubmed publisher

Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301-7 pubmed publisher

Woyach J, Ruppert A, Rai K, Lin T, Geyer S, Kolitz J, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013;31:440-7 pubmed publisher

Wu J, Huang R, Wang C, Liu W, Wang J, Weng X, et al. Thiol-inducible direct fluorescence monitoring of drug release. Org Biomol Chem. 2013;11:580-5 pubmed publisher

Gellerman G, Baskin S, Galia L, Gilad Y, Firer M. Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptide. Anticancer Drugs. 2013;24:112-9 pubmed publisher

Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol. 2012;30:4524-32 pubmed publisher

Oscier D, Rose Zerilli M, Winkelmann N, Gonzalez De Castro D, Gómez B, Forster J, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121:468-75 pubmed publisher

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess. 2012;16:1-253, iii-iv pubmed

Li W, Yan X, Shi C, Zhang A. Chlorambucil for patients with primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;:CD008714 pubmed publisher

Xie G, Xu J, Ye C, Chen D, Xu C, Yang L, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults. PLoS ONE. 2012;7:e44330 pubmed publisher

Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy M, Wickham N, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia. 2013;27:1172-4 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Wenlock M, Barton P, Luker T. Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design. Bioorg Med Chem Lett. 2011;21:3550-6 pubmed publisher

Descôteaux C, Leblanc V, Brasseur K, Gupta A, Asselin E, Bérubé G. Synthesis of D- and L-tyrosine-chlorambucil analogs active against breast cancer cell lines. Bioorg Med Chem Lett. 2010;20:7388-92 pubmed publisher

Goff R, Thorson J. Assessment of chemoselective neoglycosylation methods using chlorambucil as a model. J Med Chem. 2010;53:8129-39 pubmed publisher

Leiris S, Lucas M, Dupuy d Angeac A, Morere A. Synthesis and biological evaluation of cyclic nitrogen mustards based on carnitine framework. Eur J Med Chem. 2010;45:4140-8 pubmed publisher

Gupta A, Saha P, Descôteaux C, Leblanc V, Asselin E, Bérubé G. Design, synthesis and biological evaluation of estradiol-chlorambucil hybrids as anticancer agents. Bioorg Med Chem Lett. 2010;20:1614-8 pubmed publisher

Toropov A, Toropova A, Raska I, Benfenati E. QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. Eur J Med Chem. 2010;45:1639-47 pubmed publisher

Varma M, Obach R, Rotter C, Miller H, Chang G, Steyn S, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53:1098-108 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Evers B, Schut E, van der Burg E, Braumuller T, Egan D, Holstege H, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res. 2010;16:99-108 pubmed publisher

Kosseifi S, Vyas B, Vyas H, Krishnaswamy G, Smith S. Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature. Tenn Med. 2009;102:33-6 pubmed

Yuan J, Johnson R, Huang R, Wichterman J, Jiang H, Hayton K, et al. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol. 2009;5:765-71 pubmed publisher

Onnis V, Cocco M, Fadda R, Congiu C. Synthesis and evaluation of anticancer activity of 2-arylamino-6-trifluoromethyl-3-(hydrazonocarbonyl)pyridines. Bioorg Med Chem. 2009;17:6158-65 pubmed publisher

Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, et al. Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. Eur J Med Chem. 2009;44:4455-60 pubmed publisher

Varma M, Feng B, Obach R, Troutman M, Chupka J, Miller H, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52:4844-52 pubmed publisher

Pedersen P, Christensen M, Ruysschaert T, Linderoth L, Andresen T, Melander F, et al. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs. J Med Chem. 2009;52:3408-15 pubmed publisher

Shervington L, Smith N, Norman E, Ward T, Phillips R, Shervington A. To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines. Eur J Med Chem. 2009;44:2944-51 pubmed publisher

Santana L, González Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, et al. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008;51:6740-51 pubmed publisher

Libnow S, Methling K, Hein M, Michalik D, Harms M, Wende K, et al. Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines. Bioorg Med Chem. 2008;16:5570-83 pubmed publisher

Obach R, Lombardo F, Waters N. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-405 pubmed publisher

Reux B, Weber V, Galmier M, Borel M, Madesclaire M, Madelmont J, et al. Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives. Bioorg Med Chem. 2008;16:5004-20 pubmed publisher

Koutsourea A, Fousteris M, Arsenou E, Papageorgiou A, Pairas G, Nikolaropoulos S. Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters. Bioorg Med Chem. 2008;16:5207-15 pubmed publisher

Kaur N, Delcros J, Imran J, Khaled A, Chehtane M, Tschammer N, et al. A comparison of chloroambucil- and xylene-containing polyamines leads to improved ligands for accessing the polyamine transport system. J Med Chem. 2008;51:1393-401 pubmed publisher

Moda T, Montanari C, Andricopulo A. Hologram QSAR model for the prediction of human oral bioavailability. Bioorg Med Chem. 2007;15:7738-45 pubmed

Perjesi P, Das U, De Clercq E, Balzarini J, Kawase M, Sakagami H, et al. Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells. Eur J Med Chem. 2008;43:839-45 pubmed

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

Kalambokis G, Stefanou D, Arkoumani E, Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia. Eur J Haematol. 2004;73:139-42 pubmed

Passerini P, Ponticelli C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin Nephrol. 2003;23:355-61 pubmed

Machado S, Alves R, Lima M, Leal I, Massa A. Cutaneous necrobiotic xanthogranuloma (NXG)--successfully treated with low dose chlorambucil. Eur J Dermatol. 2001;11:458-62 pubmed

Panasci L, Paiement J, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res. 2001;7:454-61 pubmed

Waselenko J, Grever M, Beer M, Lucas M, Byrd J. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Semin Oncol. 2000;27:44-51 pubmed

Ansell B. Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis). J Rheumatol. 1999;26:765-6 pubmed

Khong H, McCarthy J. Chlorambucil-induced pulmonary disease: a case report and review of the literature. Ann Hematol. 1998;77:85-7 pubmed

Muller C, Christodoulopoulos G, Salles B, Panasci L. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood. 1998;92:2213-9 pubmed

Morrow C, Smitherman P, Diah S, Schneider E, Townsend A. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem. 1998;273:20114-20 pubmed

Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla N, et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica. 1997;82:16-20 pubmed

Salloum E, Khan K, Cooper D. Chlorambucil-induced seizures. Cancer. 1997;79:1009-13 pubmed

Begleiter A, Mowat M, Israels L, Johnston J. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma. 1996;23:187-201 pubmed

Mohr M, Kingreen D, Ruhl H, Huhn D. Interstitial lung disease--an underdiagnosed side effect of chlorambucil?. Ann Hematol. 1993;67:305-7 pubmed

Rinchik E, Flaherty L, Russell L. High-frequency induction of chromosomal rearrangements in mouse germ cells by the chemotherapeutic agent chlorambucil. Bioessays. 1993;15:831-6 pubmed

Torricelli R, Kurer S, Kroner T, Wuthrich B. [Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review]. Schweiz Med Wochenschr. 1995;125:1870-3 pubmed

Palmer R, Denman A. Malignancies induced by chlorambucil. Cancer Treat Rev. 1984;11:121-9 pubmed

Carr M. Chlorambucil induced pulmonary fibrosis: report of a case and review. Va Med. 1986;113:677-80 pubmed

Vandenberg S, Kulig K, Spoerke D, Hall A, Bailie V, Rumack B. Chlorambucil overdose: accidental ingestion of an antineoplastic drug. J Emerg Med. 1988;6:495-8 pubmed

Maugars Y, Couverchel L, Guenel Y, Bureau L, Buzelin F, Prost A. [Renal amyloidosis in rheumatoid polyarthritis stabilized for 13 years with chlorambucil]. Rev Rhum Mal Osteoartic. 1990;57:41-4 pubmed

Giles F, Smith M, Goldstone A. Chlorambucil lung toxicity. Acta Haematol. 1990;83:156-8 pubmed

Luqmani R, Palmer R, Bacon P. Azathioprine, cyclophosphamide and chlorambucil. Baillieres Clin Rheumatol. 1990;4:595-619 pubmed